← 홈

Antibody

1,230개 · ADC 1032 · Antibody 4683 · CGT 2713 · 다음 갱신 D-8 · 마지막 7월 21일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 1,230개
AntibodyCstaleRegeneronPhase 2

Cemiplimab (Cemiplimab)

Breast Neoplasms; Breast Cancer · Solid Tumor

#SolidTumor#Antibody#Phase2#인기#항체+5
효능 ORR 44%임상시험 84상태 RECRUITING
AntibodyAstaleRocheGovitecanPhase 3

carboplatin-etoposide (Atezolizumab + chemotherapy, Atezolizumab + chemotherapy (carboplatin-etoposide))

Extensive Stage Small Cell Lung Cancer · Extensive Stage Small Cell Lung Cancer

#ExtensiveStageSmallCellLungCance#Antibody#Phase3#인기#항체+5
효능 ORR 100%임상시험 83상태 RECRUITING
AntibodyBstaleAmgenPhase 3

Blinatumomab (Blinatumomab)

B Acute Lymphoblastic Leukemia; B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 · Precursor Cell Lymphoblastic Leukemia-Ly

#PrecursorCellLymphoblasticLeukem#Antibody#Phase3#인기#항체+5
효능 ORR 11.1%임상시험 83상태 RECRUITING
AntibodyBstaleAmgenPhase 3

Panitumumab (Panitumumab)

Colorectal Cancer; Resectable Colorectal Carcinoma · Head and Neck Squamous Cell Carcinoma

#HeadandNeckSquamousCellCarcinoma#Antibody#Phase3#인기#항체+5
효능 ORR 77.3%임상시험 83상태 RECRUITING
AntibodyCstaleJiangsu HengruiPhase 2

Camrelizumab (Camrelizumab)

Advanced Hepatocellular Carcinoma (HCC) · HER2

#HER2#Antibody#Phase2#인기#항체+5
임상시험 78상태 RECRUITING
AntibodyCstaleNovartis PharmaceuticalsApproved

Abatacept (Abatacept)

Rheumatoid Arthritis · Rheumatoid Arthritis

#RheumatoidArthritis#Antibody#Approved#인기#항체+4
효능 ORR 6.35%임상시험 72상태 ACTIVE
AntibodyCstaleMiltenyi Biomedicine GmbHPhase 3

Alemtuzumab (Alemtuzumab)

Leukemia; Lymphoma · Fanconi Anemia

#FanconiAnemia#Antibody#Phase3#인기#항체+5
효능 ORR 33%임상시험 71상태 DISCONTINUED
AntibodyBstaleRocheApproved

Mabthera (Mabthera)

Rheumatoid Arthritis · FRα

#FR#Antibody#Approved#인기#항체+5
효능 ORR 84.7%임상시험 69상태 ACTIVE
AntibodystaleRocheApproved

Omalizumab (Omalizumab)

Chronic Rhinosinusitis With Nasal Polyps (CRSwNP); Chronic Rhinosinusitis (CRS) · Persistent Allergic Asthma

#PersistentAllergicAsthma#Antibody#Approved#인기#항체+5
임상시험 67상태 ACTIVE
AntibodystaleShanghai Shengdi Pharmaceutical…vedotin (RC48) in combinati…Phase 2

Adebrelimab (Adebrelimab)

Pancreatic Cancer · Advanced Solid Tumors

#AdvancedSolidTumors#Antibody#Phase2#인기#항체+5
임상시험 66상태 RECRUITING
AntibodystaleHoffmann-La Rochevedotin plus bendamustine a…Phase 3

Glofitamab (Glofitamab)

Diffuse Large B Cell Lymphoma (DLBCL); High Grade B Cell Lymphoma · Chronic Lymphocytic Leukemia

#ChronicLymphocyticLeukemia#Antibody#Phase3#인기#항체+5
임상시험 66상태 RECRUITING
AntibodystaleElevation OncologyDeruxtecan]Phase 1

CYRAMZA® (Ramucirumab, Ramucirumab (CYRAMZA®))

Stomach Neoplasm; Gastrointestinal Neoplasms · Stomach Neoplasm

#StomachNeoplasm#Antibody#Phase1#인기#항체+5
효능 ORR 44.7%임상시험 66상태 DISCONTINUED
AntibodystaleTakedaPhase 2

Vedolizumab (Vedolizumab)

Ulcerative Colitis and Crohn's Disease · Colitis

#Colitis#Antibody#Phase2#인기#항체+5
효능 ORR 1%임상시험 66상태 ACTIVE
AntibodystaleAmgenPhase 3

Denosumab (Denosumab)

Postmenopausal Osteoporosis · Giant Cell Tumor of Bone

#GiantCellTumorofBone#Antibody#Phase3#인기#항체+4
효능 ORR 16.7%임상시험 65상태 ACTIVE
AntibodystaleAstraZenecavedotin combined with pembr…Phase 3

Durvalumab (MEDI4736, MEDI4736 (Durvalumab))

Non-Small-Cell Lung Carcinoma NSCLC · Advanced Solid Tumors

#AdvancedSolidTumors#Antibody#Phase3#인기#항체+5
효능 ORR 36.3%임상시험 65상태 ACTIVE
AntibodystaleNovartisPhase 3

Ofatumumab (Ofatumumab)

Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma · Leukemia

#Leukemia#Antibody#Phase3#인기#항체+5
효능 ORR 78.4%임상시험 65상태 RECRUITING
AntibodystaleAkeso-drivenPhase 2

cadonilimab (cadonilimab)

Metastatic HER2 Positive Gastroesophageal Junction Cancer · Salivary Gland Carcinoma

#SalivaryGlandCarcinoma#Antibody#Phase2#인기#항체+5
임상시험 65상태 RECRUITING
AntibodystaleBelfast Health and Social Care …Approved

Golimumab (Golimumab)

Psoriatic Arthritis; Psoriasis · Chronic Nonbacterial Osteomyelitis

#ChronicNonbacterialOsteomyelitis#Antibody#Approved#인기#항체+5
효능 ORR 0.27%임상시험 64상태 DISCONTINUED
AntibodystaleGenentech, Inc.Phase 3

Tiragolumab (Tiragolumab)

Multiple Myeloma; Non-Hodgkin Lymphoma · Urothelial Carcinoma

#UrothelialCarcinoma#Antibody#Phase3#인기#항체+5
효능 ORR 77.3%임상시험 64상태 ACTIVE
AntibodystaleRochePhase 3

atezolizumab (Tecentriq, Atezolizumab + Bevacizumab)

Venous Thrombosis · Gastric Adenocarcinoma

#GastricAdenocarcinoma#Antibody#Phase3#인기#항체+5
효능 ORR 49.3%임상시험 63상태 RECRUITING

3 / 62 페이지

← 이전다음 →